Investigational Treatment Shows Potential to Supress Memory Loss

Video

Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.

MENTAL HEALTH MINUTE

Aaron Burstein, PharmD, senior vice president of vTv Therapeutics, shares the history and current status of development of azeliragon for the treatment of dementia and diabetes, including results recently presented at the 2020 Alzheimer's Association International Conference.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024
Article
What Will the Future of Alzheimer Disease Treatment Look Like?

What Will the Future of Alzheimer Disease Treatment Look Like?

July 23rd 2021
Podcast
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From the Pages of Psychiatric Times: March 2024

March 30th 2024
Article
A Conversation With Drew Ramsey, MD, on Nutrition and Mental Health

A Conversation With Drew Ramsey, MD, on Nutrition and Mental Health

March 9th 2021
Podcast
FDA

Donanemab Delay: FDA Calls for Last-Minute Meeting to Discuss Safety and Efficacy

March 8th 2024
Article
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.